Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study

NCT ID: NCT01509781

Last Updated: 2015-10-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this prospective randomized study is to perform qualitative and quantitative comparisons between the insertion of traditional suction drains (Arm: Suction drain) versus the application of absorbable adaptive sutures (Arm: Adaptive suture) following simplex mastectomy or modified radical mastectomy in the light of the total volume of withdrawn serum from wound cavity, the extent of early postoperative analgesic requirements and quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

in Situ Breast Cancer Invasive Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Suction drain

Patients in Arm A undergo simplex mastectomy or modified radical mastectomy. One plastic Redon drain (16 Ch) is placed after simplex mastectomy and two plastic Redon drains (16 Ch each) following modified radical mastectomy.

Group Type ACTIVE_COMPARATOR

Insertion of suction drain(s) following mastectomy

Intervention Type PROCEDURE

One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.

Adaptive suture

Following mastectomy, wound cavity is closed with adaptive skin sutures. No suction drain is inserted.

Group Type EXPERIMENTAL

Adaptive skin sutures.

Intervention Type PROCEDURE

Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insertion of suction drain(s) following mastectomy

One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.

Intervention Type PROCEDURE

Adaptive skin sutures.

Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* female patients with primary unilateral, stage 0, I or II, T3N1M0 breast cancer necessitating simple or modified radical mastectomy

Exclusion Criteria

* age above 75 years and bad general state
* pregnancy
* autoimmune disease
* non-radical excision
* mastitis carcinomatosis
* lymphangitis carcinomatosis
* wound infection necessitating treatment
Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Oncology, Hungary

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Zoltan Matrai

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Miklos Kasler, M.D., Ph.D., D.Sc., Prof.

Role: PRINCIPAL_INVESTIGATOR

National Institute of Oncology

Laszlo Toth, M.D., Ph.D., Prof.

Role: STUDY_CHAIR

National Institute of Oncology

Ferenc Renyi Vamos, M.D., Ph.D.

Role: STUDY_CHAIR

National Institute of Oncology

Akos Savolt, M.D.

Role: STUDY_CHAIR

National Institute of Oncology

Emil Farkas, M.D.

Role: STUDY_CHAIR

National Institute of Oncology

Ildiko Horti, M.D.

Role: STUDY_CHAIR

National Institute of Oncology

Zoltan Matrai, M.D.

Role: PRINCIPAL_INVESTIGATOR

National Institute of Oncology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institute of Oncology

Budapest, Budapest, Hungary

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Hungary

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zoltan Matrai, M.D.

Role: CONTACT

+36 1 224 8600 ext. 3302

Laszlo Toth, M.D., Ph.D.

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zoltan Matrai, M.D.

Role: primary

+3612248600 ext. 3302

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MRM-987/2011

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.